多巴胺转运体99mTc-TRODAT-1 SPECT显像在帕金森病诊断中的研究进展

doi:10.3969/j.issn.1004-583X.2022.05.015

摘要/Abstract

摘要：

帕金森病(Parkinson’s disease,PD)是一种进行性神经退行性疾病,其患病率为0.1%~0.2%。方便、可靠的辅助检查项目对PD的诊断至关重要。^99mTc-TRODAT-1可通过单光子发射计算机断层成像术(single photon emission computed tomography,SPECT)进行多巴胺转运蛋白成像,该技术现已被应用于PD的临床诊断。本文主要通过对^99mTc-TRODAT-1 SPECT显像的基本原理、在PD诊断及鉴别诊断中的应用进行综述,旨在为PD的临床诊断提供理论依据。

关键词: 帕金森病, 多巴胺质膜转运蛋白质类, 单光子发射计算机断层成像术, ^99mTc-TRODAT-1

中图分类号:

R742.5

王璐璐, 董露露, 王天俊. 多巴胺转运体^99mTc-TRODAT-1 SPECT显像在帕金森病诊断中的研究进展[J]. 临床荟萃, 2022, 37(5): 463-466.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2022.05.015

https://huicui.hebmu.edu.cn/CN/Y2022/V37/I5/463

参考文献 31

[1]	Lee JY, Yoon EJ, Kim YK, et al. Nonmotor and dopamine transporter change in REM sleep behavior disorder by olfactory impairment[J]. J Mov Disord, 2019, 12(2): 103-112.
[2]	Hayes MT. Parkinson’s disease and parkinsonism[J]. Am J Med, 2019, 132(7):802-807. doi: 10.1016/j.amjmed.2019.03.001 URL
[3]	Raza C, Anjum R, Shakeel N. Parkinson’s disease: Mechanisms, translational models and management strategies[J]. Life Sci, 2019, 226(2):77-90. doi: 10.1016/j.lfs.2019.03.057 URL
[4]	Mittal BR, Sood A, Shukla J, et al. 99mTc-TRODAT-1 SPECT/CT imaging as a complementary biomarker in the diagnosis of parkinsonian syndromes[J]. Nucl Med Commun, 2018, 39(4):312-318. doi: 10.1097/MNM.0000000000000802 URL
[5]	Kung MP, Stevenson DA, Plossl K, et al. (99m)Tc-TRODAT-1 SPECT-1:A novel technetium-99mcomplex as a dopamine transporter imaging agent[J]. Eur J Nucl Med, 1997, 24(4):372-380. doi: 10.1007/BF00881808 pmid: 9096087
[6]	Sharp ME, Duncan K, Foerde K, et al. Dopamine is associated with prioritization of reward-associated memories in Parkinson’s disease[J]. Brain, 2020, 143(8):2519-2531. doi: 10.1093/brain/awaa182 URL
[7]	Tripathi M, Kumar A, Bal C. Neuroimaging in parkinsonian disorders[J]. Neurol India, 2018, 66(5):S68-S78.
[8]	Ikeda K, Ebina J, Kawabe K, et al. Dopamine transporter imaging in parkinson disease: Progressive changes and therapeutic modification after anti-parkinsonian medications[J]. Intern Med, 2019, 58(12):1665-1672. doi: 10.2169/internalmedicine.2489-18 URL
[9]	Sun Y, Liu C, Chen Z, et al. A phase 2, open-label, multi-center study to evaluate the efficacy and safety of (99m)Tc-TRODAT-1 SPECT to detect Parkinson’s disease[J]. Ann Nucl Med, 2020, 34(1):31-37. doi: 10.1007/s12149-019-01412-2 pmid: 31646428
[10]	Kuten J, Linevitz A, Lerman H, et al. [18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept study[J]. J Integr Neurosci, 2020, 19(3):489-494. doi: 10.31083/j.jin.2020.03.196 URL
[11]	Mittal BR, Sood A, Shukla J, et al. 99mTc-TRODAT-1 SPECT/CT imaging as a complementary biomarker in the diagnosis of parkinsonian syndromes[J]. Nucl Med Commun, 2018, 39(4):312-318. doi: 10.1097/MNM.0000000000000802 URL
[12]	Bor-Seng-Shu E, Pedroso JL, Felicio AC, et al. Substantia nigra echogenicity and imaging of striatal dopamine transporters in Parkinson's disease: A cross-sectional study[J]. Parkinsonism Relat Disord, 2014, 20(5):477-481. doi: 10.1016/j.parkreldis.2014.01.015 URL
[13]	Arena JE, Urrutia L, Falasco G, et al. Correlation between (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in patients with Parkinson's disease: A pilot study[J]. Radiol Bras, 2021, 54(4):232-237. doi: 10.1590/0100-3984.2020.0087 URL
[14]	Mittal BR, Sood A, Shukla J, et al. 99mTc-TRODAT-1 SPECT/CT imaging as a complementary biomarker in the diagnosis of parkinsonian syndromes[J]. Nucl Med Commun, 2018, 39(4):312-318. doi: 10.1097/MNM.0000000000000802 URL
[15]	Sasannezhad P, Juibary AG, Sadri K, et al. (99m)Tc-TRODAT-1 SPECT imaging in early and late onset Parkinson's disease[J]. Asia Ocean J Nucl Med Biol, 2017, 5(2):114-119. doi: 10.22038/aojnmb.2017.8844 pmid: 28660222
[16]	Huang WS, Lin SZ, Lin JC, et al. Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging[J]. J Nucl Med, 2001, 42(9):1303-1308. pmid: 11535717
[17]	Fornari L, Da S, Muratt C, et al. Striatal dopamine correlates to memory and attention in Parkinson's disease[J]. Am J Nucl Med Mol Imaging, 2021, 11(1):10-19.
[18]	Patel A, Simon S, et al. Dopamine transporter imaging with Tc-99m TRODAT-1 SPECT in Parkinson's disease and its correlation with clinical disease severity[J]. Asia Ocean J Nucl Med Biol, 2019, 7(1):22-28. doi: 10.22038/AOJNMB.2018.30356.1208 pmid: 30705908
[19]	Gupta V, Ranjan R, Verma R, et al. Correlation of 99m Tc-TRODAT-1 SPECT imaging findings and clinical staging of parkinson disease[J]. Clin Nucl Med, 2019, 44(5):347-350. doi: 10.1097/RLU.0000000000002529 URL
[20]	Pifarre P, Cuberas G, Hernandez J, et al. Cortical and subcortical patterns of I-123 iodobenzamide SPECT in striatal D(2) receptor parkinsonisms[J]. Clin Nucl Med, 2010, 35(4):228-233. doi: 10.1097/RLU.0b013e3181d18cb3 URL
[21]	Hsu SY, Yeh LR, Chen TB, et al. Classification of the multiple stages of Parkinson's disease by a deep convolution neural network based on (99m)Tc-TRODAT-1 SPECT images[J]. Molecules, 2020, 25(20):253-255. doi: 10.3390/molecules25020253 URL
[22]	Howland EJ, Palmer J, Lumley M, et al. Acquired factor Ⅷ inhibitors as a cause of primary post-partum haemorrhage[J]. Eur J Obstet Gynecol Reprod Biol, 2002, 103(1):97-98. pmid: 12039476
[23]	Hossein-Tehrani MR, Ghaedian T, Hooshmandi E, et al. Brain TRODAT-SPECT versus MRI morphometry in distinguishing early mild Parkinson's disease from other extrapyramidal syndromes[J]. J Neuroimaging, 2020, 30(5):683-689. doi: 10.1111/jon.12740 pmid: 32557946
[24]	Evers L, Krijthe JH, Meinders MJ, et al. Measuring Parkinson's disease over time: The real-world within-subject reliability of the MDS-UPDRS[J]. Mov Disord, 2019, 34(10):1480-1487. doi: 10.1002/mds.27790 URL
[25]	Li DH, Zhang LY, Hu YY, et al. Transcranial sonography of the substantia nigra and its correlation with DAT-SPECT in the diagnosis of Parkinson's disease[J]. Parkinsonism Relat Disord, 2015, 21(8):923-928. doi: 10.1016/j.parkreldis.2015.05.024 URL
[26]	Wang X, Cao Z, Liu G, et al. Clinical characteristics and electrophysiological biomarkers of Parkinson's disease developed from essential tremor[J]. Front Neurol, 2020, 11:471-474. doi: 10.3389/fneur.2020.00471 URL
[27]	Fallahi B, Esmaeili A, Beiki D, et al. Evaluation of (99m)Tc-TRODAT-1 SPECT in the diagnosis of Parkinson's disease versus other progressive movement disorders[J]. Ann Nucl Med, 2016, 30(2):153-162. doi: 10.1007/s12149-015-1042-y pmid: 26612262
[28]	Kaasinen V, Vahlberg T, Stoessl AJ, et al. Dopamine receptors in Parkinson's disease: A meta-analysis of imaging studies[J]. Mov Disord, 2021, 36(8):1781-1791. doi: 10.1002/mds.28632 URL
[29]	Kochem A, Orio M, Jarjayes O, et al. Unsymmetrical one-electron oxidized ni(II)-bis(salicylidene) complexes: A protonation-induced shift of the oxidation site[J]. Chem Commun (Camb), 2010, 46(36):6765-6767. doi: 10.1039/c0cc01775b URL
[30]	Lu CS, Weng YH, Chen MC, et al. 99mTc-TRODAT-1 imaging of multiple system atrophy[J]. J Nucl Med, 2004, 45(1):49-55.
[31]	Tzen KY, Lu CS, Yen TC, et al. Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1[J]. J Nucl Med, 2001, 42(3):408-413. pmid: 11337515

多巴胺转运体^99mTc-TRODAT-1 SPECT显像在帕金森病诊断中的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 31

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王九雪, 李娜, 靳玮, 王硕, 常雅君, 王天俊. 帕金森病患者血清尿酸、同型半胱氨酸和胱抑素C水平与运动症状及认知功能的相关性[J]. 临床荟萃, 2024, 39(2): 125-129.
[2]	周正新, 梁秋雄, 陈江瑛. 胰高血糖素样肽-1在帕金森病“肠-脑轴”中的作用研究进展[J]. 临床荟萃, 2023, 38(9): 855-858.
[3]	张娜文, 黄少敏, 田利民. 2型糖尿病与帕金森病相关性研究的进展[J]. 临床荟萃, 2023, 38(9): 845-850.
[4]	王璐璐, 董露露, 江超, 王九雪, 常雅君, 王天俊. 弥散张量成像评估帕金森病合并非运动症状患者脑微结构的研究进展[J]. 临床荟萃, 2023, 38(2): 189-192.
[5]	孙亚南, 郝一峰, 李晓红. 肛门括约肌肌电图对多系统萎缩与帕金森病鉴别诊断价值的Meta分析[J]. 临床荟萃, 2022, 37(6): 490-496.
[6]	郭畅, 沈慧楠, 孙艺萌, 王东玉. 血脂、同型半胱氨酸与帕金森病合并认知障碍相关性[J]. 临床荟萃, 2022, 37(2): 128-132.
[7]	李文君, 张策, 刘俊艳. 改善循环治疗加重帕金森病患者体位性低血压1例[J]. 临床荟萃, 2022, 37(10): 934-937.
[8]	但佳惠, 王相明, 张月辉. 磁共振成像对帕金森病诊断价值的研究进展[J]. 临床荟萃, 2021, 36(5): 476-480.
[9]	王亚平. 认知行为疗法对于帕金森病非运动症状的治疗进展[J]. 临床荟萃, 2020, 35(8): 766-768.
[10]	耿丽娟，刘晨菲，董慈，李冬，刘惠苗，顾平. 帕金森病患者昼夜节律失调性睡眠-觉醒障碍研究进展[J]. 临床荟萃, 2020, 35(8): 755-760.
[11]	刘姣1，王倩1,王东玉2. 曲唑酮对帕金森病患者情绪与睡眠质量的临床疗效[J]. 临床荟萃, 2020, 35(2): 153-157.
[12]	夏敏1，2，江一静1, 郑得忠1，2，王辉兴1，2，詹增土1，林志诚1. 体感游戏对帕金森病患者认知、步态的影响[J]. 临床荟萃, 2020, 35(10): 900-903.
[13]	方鹏洪，解冰川，马速，顾平. 帕金森病患者睡眠—觉醒障碍的临床表现及治疗进展[J]. 临床荟萃, 2019, 34(9): 855-860.
[14]	李晶雪，李哲，王天俊. 帕金森病伴发抑郁发病机制及治疗的研究进展[J]. 临床荟萃, 2019, 34(8): 759-763.
[15]	吝娜1，曹磊2. 水通道蛋白4在中枢神经系统疾病中的研究进展[J]. 临床荟萃, 2019, 34(6): 567-571.